MTOR and breast carcinoma: They used a combination of therapy with a CDK inhibitor (roscovitine) plus a b-Raf-targeting pan-kinase inhibitor (sorafenib) or an mTOR inhibitor (rapamycin) to arrest the G1/S cell cycle in breast cancer cells; thus, the b-Raf-ERK1/2-mTOR signaling pathway could be suppressed (Duong et al., 2012).